# Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration

Study · id `cardio:ct-nct01458405` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01458405](<https://clinicaltrials.gov/study/NCT01458405>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01458405

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Heart failure; Acute care and long-term living  

## In plain language

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 135 participants.

## Technical summary

Registry record NCT01458405. Randomized; triple masking; primary purpose treatment. Start 2012-11-13 (actual); primary completion 2017-07-03 (actual). Results posted on 2024-04-09.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 1/2
- Enrolled: 135 participants (enrolled count; ClinicalTrials.gov record NCT01458405, source copy `cardio:ctgov-nct01458405-2024-04-09`, retrieved 2026-10-26)
- Started: 2012-11-13 (actual) (ClinicalTrials.gov record NCT01458405, source copy `cardio:ctgov-nct01458405-2024-04-09`, retrieved 2026-10-26)
- Primary completion: 2017-07-03 (actual) (ClinicalTrials.gov record NCT01458405, source copy `cardio:ctgov-nct01458405-2024-04-09`, retrieved 2026-10-26)
- Completion: 2019-02-28 (actual) (ClinicalTrials.gov record NCT01458405, source copy `cardio:ctgov-nct01458405-2024-04-09`, retrieved 2026-10-26)
- Results first posted: 2024-04-09 (ClinicalTrials.gov record NCT01458405, source copy `cardio:ctgov-nct01458405-2024-04-09`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01458405, source copy `cardio:ctgov-nct01458405-2024-04-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01458405-2024-04-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration
- Acronym: ALLSTAR
- Condition: Myocardial Infarction
- Intervention (Biological): CAP-1002 Allogeneic Cardiosphere-Derived Cells
- Intervention (Drug): Placebo
- Lead sponsor: Capricor Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: National Institutes of Health (NIH)
- Collaborator class: NIH
- Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator class: NIH
- Collaborator: California Institute for Regenerative Medicine (CIRM)
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry lists this organization as a collaborator: National Institutes of Health (`cardio:nih`)
- Registry lists this organization as a collaborator: National Heart, Lung, and Blood Institute (`cardio:nhlbi`)
- Registry lists this organization as a collaborator: California Institute for Regenerative Medicine (CIRM) (`cardio:org-california-institute-for-regenerative-medicine-cirm`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial (`cardio:pubmed-32749459`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of cardiosphere-derived cells on segmental myocardial function after myocardial infarction: ALLSTAR randomised clinical trial (`cardio:pubmed-34233913`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: ee7950ec077edd3a6f6cdb027663e59cc6409e89ffa7ac8c93478f73493c1dfe
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
